Literature DB >> 12210350

Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy.

Johan L K Van Hove1, Rita Van Damme-Lombaerts, Stephanie Grünewald, Heidi Peters, Boudewijn Van Damme, Jean-Pierre Fryns, Jozef Arnout, Ron Wevers, E Regula Baumgartner, Brian Fowler.   

Abstract

Two siblings, a boy age 12 and his sister age 4 years, presented with proteinuria and hematuria, hypertension, and chronic hemolytic anemia. At age 13 years, the boy developed an episode of severe hypertensive encephalopathy and transient renal failure. Both children are attending normal school, have no neurologic symptoms, and only minimal pigmentary retinal abnormalities. Renal biopsy showed a chronic thrombotic microangiopathic nephropathy. Both patients had hyperhomocysteinemia and mild methylmalonic aciduria. Fibroblasts showed decreased cobalamin uptake, reduced methyl- and adenosyl-cobalamin formation, and deficient incorporation of formate and propionate, compatible with the Cbl-C complementation group, but milder than that found in cells from most patients. Both patients and their father carry a balanced reciprocal translocation. Parenteral hydroxycobalamin treatment reduced the homocysteine levels, and methylmalonic acid disappeared. Increasing the dosage of hydroxycobalamin from 1 to 2.5, then 5 mg daily together with betaine, further reduced homocysteine levels (boy from 118 to 23 microM and girl from 59 to 14 microM). With this treatment, hemolysis has stopped, hematuria has disappeared, proteinuria has almost normalized, and creatinine clearance has been stable. Investigations for chronic thrombotic microangiopathy should include testing for this unusual but treatable disorder, regardless of age of presentation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210350     DOI: 10.1002/ajmg.10499

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  29 in total

Review 1.  Atypical hemolytic uremic syndrome.

Authors:  Vahid Afshar-Kharghan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria.

Authors:  Francesca Menni; Sara Testa; Sophie Guez; Gabriella Chiarelli; Luisella Alberti; Susanna Esposito
Journal:  Pediatr Nephrol       Date:  2012-03-25       Impact factor: 3.714

3.  An unusual cause of hypertension with hematuria and proteinuria: Answers.

Authors:  Michael B Stokes; Ronald Zviti; Fangming Lin; Vivette D D'Agati
Journal:  Pediatr Nephrol       Date:  2016-03-15       Impact factor: 3.714

4.  Milder clinical and biochemical phenotypes associated with the c.482G>A (p.Arg161Gln) pathogenic variant in cobalamin C disease: Implications for management and screening.

Authors:  Mohammed Almannai; Ronit Marom; Kristian Divin; Fernando Scaglia; V Reid Sutton; William J Craigen; Brendan Lee; Lindsay C Burrage; Brett H Graham
Journal:  Mol Genet Metab       Date:  2017-06-29       Impact factor: 4.797

Review 5.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 6.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 7.  An Introduction to Pharmacotherapy for Inborn Errors of Metabolism.

Authors:  Aaron A Harthan
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

8.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

9.  Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte.

Authors:  James D Weisfeld-Adams; Mark A Morrissey; Brian M Kirmse; Bobbie R Salveson; Melissa P Wasserstein; Peter J McGuire; Sherlykutty Sunny; Jessica L Cohen-Pfeffer; Chunli Yu; Michele Caggana; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-09-27       Impact factor: 4.797

10.  Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature.

Authors:  Utkarsh Acharya; Jen-Tzer Gau; William Horvath; Paolo Ventura; Chung-Tsen Hsueh; Wayne Carlsen
Journal:  J Hematol Oncol       Date:  2008-12-18       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.